669 related articles for article (PubMed ID: 18282788)
21. [Bisphosphonate-associated osteonecrosis of the jaw].
Abu-Id MH; Açil Y; Gottschalk J; Kreusch T
Mund Kiefer Gesichtschir; 2006 Mar; 10(2):73-81. PubMed ID: 16456688
[TBL] [Abstract][Full Text] [Related]
22. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
23. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
Favia G; Pilolli GP; Maiorano E
J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
[TBL] [Abstract][Full Text] [Related]
24. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
[TBL] [Abstract][Full Text] [Related]
25. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
27. Osteonecrosis of the jaw associated with pamidronate therapy.
Zarychanski R; Elphee E; Walton P; Johnston J
Am J Hematol; 2006 Jan; 81(1):73-5. PubMed ID: 16369966
[TBL] [Abstract][Full Text] [Related]
28. Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series.
Ferlito S; Liardo C; Puzzo S
Minerva Stomatol; 2010; 59(11-12):593-601. PubMed ID: 21217623
[TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
30. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
[TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
32. Osteonecrosis of the jaw: who gets it, and why?
Reid IR
Bone; 2009 Jan; 44(1):4-10. PubMed ID: 18948230
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
34. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
Badros A; Weikel D; Salama A; Goloubeva O; Schneider A; Rapoport A; Fenton R; Gahres N; Sausville E; Ord R; Meiller T
J Clin Oncol; 2006 Feb; 24(6):945-52. PubMed ID: 16484704
[TBL] [Abstract][Full Text] [Related]
36. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.
Brooks JK; Gilson AJ; Sindler AJ; Ashman SG; Schwartz KG; Nikitakis NG
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):780-6. PubMed ID: 17223592
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S
J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158
[TBL] [Abstract][Full Text] [Related]
39. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]